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Ethiopia, a sub-Saharan African country with high maternal and child mortality rates, has 
a low modern contraceptive prevalence of 35%; this level of utilization meets 60% of the 
demand among married and in-union women, according to the 2016 Ethiopian 
Demographic and Health Survey (EDHS). Contraceptive use among married and in-union 
women globally is 63%, meeting 78% of the demand for this group of women. In addition 
to the low contraceptive prevalence in Ethiopia, there is a difference among regions, 
running from 1% to 50%. The country has pledged to increase the national prevalence of 
modern contraceptive use to 55% (of all married women of fertile age), with a greater 
focus on long-acting methods, mainly focusing on addressing unmet need for 
contraceptives. This effort needs a substantial budget increase. The cost-effectiveness of 
scaling up modern contraceptive coverage may vary among regions, and there are no 
studies from Ethiopia that document the cost-effectiveness of scaling up contraceptive 
coverage at the subnational level.  
Objective 
The objective of the study is to analyze the cost-effectiveness of scaling up modern 
contraceptive coverage at a subnational level among Ethiopian regions and to estimate 
the budget needed for each region. This information could be useful for decision makers 
who aim to maximize the health impact and equalize coverage across regions. 
Methodology  
The analysis was conducted using a Markov model in which the status quo modern 
contraceptive coverage level of each region was compared with a scaled-up and equalized 
modern contraceptive coverage level across all regions. The model was built to simulate 
the experience of a cohort of 15-year-old reproductive females who are not initially 
sexually active and who may become sexually active or remain sexually inactive, in 
relation to modern contraceptive usage status over the time horizon of women’s 
reproductive years. The modeling was based on secondary data. Transition probabilities 
and healthcare provider–related costs were extracted from the latest EDHS and relevant 
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published papers. The disability weights were collected from the Global Burden of 
Disease study. All the costs and benefits were discounted by 3% every year. The primary 
outcome of this study is cost per quality-adjusted life year (QALY) gained, which is the 
result of the reduction in unintended pregnancies. The number of averted unintended 
pregnancies and unwanted clinical events, such as abortion and complicated pregnancy, 
are secondary outcomes. I also estimated the budget needed to scale up the intervention 
in all regions. I did deterministic and probabilistic sensitivity analyses to check the impact 
of the uncertainty of parameter estimates on the cost-effectiveness of the intervention and 
the robustness of findings in the face of parameter uncertainty. Twelve models were built, 
11 for the nine regions and two city administrations and one to be used as a national-level 
model. Subsequent analysis was conducted separately and compiled for regional 
comparison. TreeAge Pro version 2020 and Microsoft Excel were used for building the 
model and analysis. 
Research Ethics 
As the study used publicly available reports and published studies as data sources, ethical 
clearance was not necessary. 
Results  
The intervention, which is scaling up modern contraceptive coverage, dominates the 
status quo coverage. Scaling up coverage to 55% is cost saving in all regions since the 
intervention results in more QALYs gained at a lower cost. Scaling up modern 
contraceptive prevalence to an average of 55% for 15-year-old females in their 
reproductive age will result in savings of about US$49 million at the national level (range: 
from US$0.16 million to US$24 million in different regions). The intervention also 
reduces close to 700 thousand unintended pregnancies. The one-way sensitivity analysis 
shows that the incremental cost-effectiveness ratio (ICER) is most sensitive to the cost of 
modern contraceptives and the cost of delivery, especially in Addis Ababa (AA) , Tigray, 
and the Southern Nations, Nationalities, and Peoples’ (SNNP) regions. In the probabilistic 
sensitivity analysis, there is a 65% probability that the intervention will be a cost saving 





The regions where the status quo coverage is low will see more QALYs gained. The per 
capita cost saved is large in Somali and Afar regions. This could be because of the low 
coverage, combined with the large rural proportion of the population. The regions with 
higher rural population proportions will have higher investment costs to implement the 
intervention and are the ones that will gain the highest return on the investment. The 
finding that scaling up contraceptive coverage is cost-effective was found to be similar in 
other studies conducted in Uganda and Indonesia. One important  limitation of this study 
is that the model has not incorporated non-health benefits and health benefits related to 
child health of increased modern contraceptive coverage. This may have resulted in 
underestimation of the cost-effectiveness of the intervention. 
Conclusion  
The results show that scaling up and equalizing modern contraceptive coverage across 
regions is not only cost-effective but could also be cost saving. This information may be 
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1. Background  
Contraceptive methods comprise any method that helps a reproductive woman to space 
or limit the number of her pregnancies (1, 2). Depending on the method used, 
contraceptives can be classified as traditional or modern. Coitus interruptus, vaginal 
douching after sexual intercourse, and the calendar method are categorized as traditional 
contraceptive methods. Oral contraceptive pills, condoms, diaphragms, cervical caps, 
injectables, implants, intrauterine devices (IUDs), and tubal ligation are regarded as 
modern contraceptive approaches (2). These modern contraceptives are also broadly 
categorized as short acting, long acting, and permanent, according to the length of the 
period over which they are capable of preventing pregnancy. Oral contraceptives, the 
barrier methods, and injectables are short-term modalities, while hormonal implants and 
IUDs are long-term modalities, and tubal ligations are a permanent modality (3). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
Contraception, in addition to the benefit of controlling family size, helps to reduce 
maternal and child mortality, empowers people, and slows population growth, and some 
of them help to prevent sexually transmitted infections (1, 4). Oral contraceptives are 
known to protect against some cancers and pelvic inflammatory disease, and barrier 
methods have a protective effect against sexually transmitted infections, including HIV 
(5). A study by Ahmed et al. from 2012 estimated that contraceptive use averted 40% of 
maternal deaths worldwide by reducing unintended pregnancies (6). The decrease in 
number of pregnancies by itself reduces maternal death because deaths related to 
pregnancy are by definition considered maternal deaths. The decline in subsequent 
fertility in women with high parity while using contraception is another way in which 
obstetric risk is reduced (6, 7). Increasing the gap between pregnancies by more than 24 
months—spacing—is also known to improve perinatal and child survival. This is because 
of the aversion of the increased risk of preterm birth, low-birth weight, and small size for 
gestation, which happens when the interpregnancy gap is less than 18 months (7). In low-
income countries, another explanation could be that the care can be continued for a child 
that would otherwise have been minimized or lost because of the birth of another child or 
because the mother had died, thus helping to reduce child mortality. Rapid population 
growth (>2%) is a threat to wellbeing in the poorest countries because of its adverse 
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social, economic, and environmental pressures (4, 8), thus increasing the importance of 
contraceptive use on the policy agenda. 
 
According to the United Nations Department of Economic and Social Affairs’ World 
Family Planning 2017 report, contraceptive use among married and in-union women 
globally was 63% and above 70% in Europe, Latin America, the Caribbean, and Northern 
America. The proportion of demand satisfied by modern methods globally is 78%. The 
proportion of needs met by modern contraceptive is just 56% in Africa, however, while 
it is more than 75% for other regions (9). As is the case for many other health indicators, 
the least developed countries have much lower contraceptive coverage than do most of 
the developed countries. This coverage gets even lower for sub-Saharan Africa, where 
the prevalence of contraceptive use is 33% among married and in-union women while it 
is 40% for less developed countries (10). As of 2017, there were 885 million reproductive-
age women in developing countries who need contraceptives, of whom 75.8 % are using 
modern contraceptives, with the remaining 24.2% classified as having unmet need. Of 
those 214 million women who had unmet need, 27.6% are using traditional contraceptive 
methods. The proportion of women who have unmet need in sub-Saharan Africa is also 
more than 20%. Because of this unmet need, 43% of all pregnancies are estimated to be 
unintended in this developing region of the world (11). 
 
Ethiopia is a low-income sub-Saharan African country with a projected population of 
more than 110 million in the year 2020. Sixty percent of this population is under 25 years 
of age. The country has nine regions and two city administrations. Eighty percent of the 
population resides in the rural part of the country. In 2016, Ethiopia had a modern 
contraceptive coverage of 35% among married women, up from 6% in the year 2000. 
However, this coverage varies by region in Ethiopia, ranging from 1% in Somali region 
to 50% in the capital, Addis Ababa (Figure 1). The figures are lower still for contraceptive 
use among all women, ranging from 1% in Somali region to 34.1% in Amhara region. 
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Figure 1. Use of modern contraceptive methods among married women by region, 
from the 2016 EDHS 
Injectables and implants are the two most commonly used modern contraceptive methods 
in Ethiopia in all regions, while female sterilization is the least common. Eighty-four 
percent of modern contraception is provided in the public sector. Health centers and 
private facilities at the same level comprise the largest share of the contraceptive service 
providers.  
Utilization of contraception can be affected by multiple socioeconomic factors. Poor 
women use contraception much less than wealthier women do, as has been shown by the 
positive concentration index in a study by Creanga et al. that aimed to assess contraceptive 
use among poor women in Africa (12). The findings were similar to those for Ethiopia, 
with coverage of modern contraception varying across the wealth quantiles from 20% in 
the poorest to 47% in the wealthiest. This inequality among wealth quantiles also shows 
up in the educational status of women. Coverage is 31% for those who have had no 
schooling while it is 51% for those who have completed secondary school (13). 
Contraceptive utilization can also be affected by geographical location of residence. The 
coverage of modern contraception in Ethiopia in urban and rural parts of the country is 
50% and 32%, respectively (13, 14). Distance from service-providing facilities, the 
availability of contraceptive methods, and availability of health professionals who can 
provide the service are other determinant factors that affect contraceptive use. Together, 
these can be described as access to contraceptives in general. The better the access, the 
better the probability of utilization of contraceptives. 
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Ethiopia has shown considerable progress on contraception and has been regarded as one 
of the emerging contraception success stories. This is mainly attributed to generous donor 
support, non-governmental and public–private partnerships, and the government’s 
establishment of a network of health-extension workers. The innovative health extension 
program that brought various existing health services close to the community helped to 
improve maternal-related health indicators (15). However, the total fertility rate (TFR) 
and population growth in Ethiopia are still at 4.6 and 2.6, respectively, meaning that if the 
country is to meet its plan to become a middle-income country, the task is still immense. 
The rights-based contraceptive approach is one strategy to address this challenge (16). 
The country has pledged to increase contraceptive prevalence among married women 
from the then status quo coverage to 55% by 2020 and to reduce the TFR to 3 by 2020 
(14). Ethiopia needs an estimated US$285 million in the period from 2015 to 2020 to 
meet these targets (17). 
2. Rationale 
Although Ethiopia’s track record with regard to contraception is good, the target 
originally set for 2020 is still a long way off. The gap can be addressed by planning for 
higher coverage among those with an unmet need for contraception and by creating the 
demand for modern contraception where it is low. The country plans to lower the TFR to 
3 by 2020, which is still a high TFR. However, the country cannot plan for a further 
lowering of the TFR because the budget needed for the already existing target needs 
health sector budgeting with a family planning focus from both the federal and regional 
governments. This could be an earmarked budget or an increase in the already existing 
budget for maternal and child health. In its “Costed Implementation Plan” of 2016, the 
Ministry of Health noted that it needs evidence-based advice to convince the government 
to put extra money toward realization of the plan (17). If the budget for modern 
contraception is to be provided by the federal government to the regions, it will also need 
to be invested cost-effectively. Cost-effectiveness of scaling up modern contraceptive 
coverage could vary by region, given the wide differences in coverage, demand, and the 
costs of scaling up. Despite searching widely for subnational cost-effectiveness analyses, 
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I was unable to find studies documenting the cost-effectiveness of scaling up 
contraceptive coverage by subgroups characterized by area of living.  
This study will produce national and regional incremental cost-effectiveness ratios 
(ICERs) that can help policymakers to make evidence-informed decisions as to whether 
scaling up and equalizing modern contraceptive coverage among regions is cost-effective 
and where among the regions such cost-effectiveness would be better.  
 
3. General and Specific Objectives 
a. General objective 
Determine the costs and effects of scaling up and equalizing coverage 
of modern contraceptive methods to reduce unmet need in all regions 
of Ethiopia by using economic modeling and sub-group analysis.  
b. Specific objectives 
i. Determine the costs of scaling up modern contraceptive methods 
for each region in Ethiopia. 
ii. Determine the effectiveness of scaling up modern contraceptive 
methods for each region in Ethiopia.  
iii. Estimate the cost-effectiveness of scaling up and equalizing 
coverage of modern contraceptive methods across regions by 
Markov modeling analysis. 
iv. Estimate the budget needed by each region to implement the new 







4.1. Model overview 
This study followed the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) statement (18)(see Annex 1). A Markov decision analytic model was 
developed to analyze the costs, effects, and cost-effectiveness of scaling up modern 
contraceptive coverage compared to the status quo situation for a cohort of 15-year-old 
females in Ethiopia, using a time horizon of women’s reproductive years, making 2016 
the baseline year. The proportion of unmet need was defined in line with the definition of 
the World Health Organization (WHO), namely, the gap between women’s reproductive 
intentions and their actual contraceptive utilization behavior (19).  
 
The model simulated the sexual activity and experience of modern contraceptive use of a 
15-year-old female in all regions and on a national level. In the analysis, the intervention 
arm was increasing the contraceptive prevalence rate to 55% coverage, a coverage level 
that was chosen because it was the initial modern contraceptive coverage target for the 
“married women” group in the FP2020 plan. The comparator was modern contraceptive 
coverage among all reproductive-age women in all regions and at the national level for 
the year 2016 (EDHS). The primary outcome of the study is cost per quality-adjusted life 
year (QALY) gained, which is the result of a reduction in unintended pregnancies. 
Clinical outcomes like number of averted unintended pregnancies (and its potential 
consequence, abortion) and complicated pregnancies are secondary outcomes. The cost 
of scaling up and equalizing modern contraceptive coverage per region is a third set of 
results of particular interest.  
 
The study looked at costs from a healthcare-provider perspective. Long-term costs and 
health outcomes were discounted at 3%, a rate commonly used in many countries (20). I 
used half the GDP per capita for this study as the willingness to pay threshold. This 
threshold is different from the WHO CHOICE’s recommendation of an ICER below one 
GDP per capita and above three GDP to define interventions as very cost-effective or not 
cost-effective, previously used in many cost-effectiveness analyses (21). Recently, such 
usage has been questioned by researchers. In a study by Woods et al., it was suggested 
7 
 
that thresholds vary with countries’ income and health care spending (22). In that study, 
assuming different levels of income elasticity, the cost-effectiveness threshold for low-
income, lower-middle-income, upper-middle-income, and higher-income countries 
ranged from as low as 3% to as high as 129% of GDP per capita (22). For my study, I 
used 50% of GDP per capita as the threshold because it was at the higher end of the 
recommended cost-effectiveness threshold for low-income countries.  
I did face validation for the model by inserting extreme values and double checking the 
input data. Deterministic and probabilistic sensitivity analyses were conducted to 
investigate the impact of model parameter uncertainty on cost-effectiveness results. The 
model was built using TreeAge Pro software, and this software and Microsoft Excel were 
used for analysis. 
4.2. Model structure 
The state transition diagram representing the Markov model is shown in Figure 2. For the 
analysis, a cohort of 15-year-old females was followed over the time horizon of their 
reproductive age (35 years). The model had six health states, the first four of which 
represented different behaviors with regard to sexual activity and modern contraceptive 
utilization, the remaining two being death states, of which one was pregnancy related and 
the other was background death from other causes. The Markov model (see Annex 2) was 
built on the following assumptions: When a sexually inactive 15-year-old reproductive-
age female becomes sexually active, she can be in one of the following three states with 
respect to utilization of contraception: a) starting to use modern contraceptives, b) 
intentionally not using contraception because she wants to get pregnant, or c) 
unintentionally not using contraception because of either a lack of access or a lack of 
individual awareness, categorizing her as a female with unmet need. Sexual activity was 
defined as sex within the previous year as reported by reproductive-age females, as per 
the EDHS. For this study, females who were using traditional contraceptive methods were 
considered to be unintentional non-users of contraceptives. 





NSA = Not sexually active  
MC = Modern contraceptives 
INC = Intentional non-user of contraceptives (those who want to get pregnant) 
UNC= Unintentional non-user of contraceptives (unmet need)  
 
Figure 2. State transition diagram describing possible health states of 
reproductive-age females 
A reproductive-age female can become “unintentionally pregnant” either because she was 
not using contraception unintentionally or because of modern contraceptive method 
failure. Those who intentionally did not use contraceptives could also become pregnant, 
defined as intentional pregnancy. Induced abortion was assumed to be zero in this group 
because the pregnancy was an intended one. However, induced abortion will be present 
in those with unintentional pregnancies. 
The age-specific proportions of reproductive-age women in all regions and at the national 
level, who were sexually active, who were using modern contraceptive methods, and who 
had an unmet need for modern contraceptives are provided in Tables 3–5. All women 
who were sexually active had a chance of becoming pregnant. The probability of 
becoming pregnant, which was adjusted for menopause with aging as per the information 
found in the EDHS, was assumed to be identical for both intentional and unintentional 
non-users of modern contraceptives, representing the probabilities of becoming pregnant 
without any contraceptive methods (Table 2) (23). The probability of becoming pregnant 
while on modern contraception was considered to be similar to the probability of modern 
contraceptive method failure. In the absence of specific data, the probability of 
transitioning from the unintentional non-user of contraception state to the intentional user 
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of contraception state was assumed to be equal to that of transitioning from the sexually 
inactive state to the intentional contraceptive user health state. Women in the modern 
contraception state can remain in the same state, discontinue using modern contraceptives 
intentionally or unintentionally, get pregnant because of method failure, or die from 
background causes. These probabilities were assumed to be similar in all regions. A 
pregnant woman will transition to all four alive health states unless maternal death 
happens. Thus, a mother will jump to the four health states with a probability specific for 
her age. The probability of becoming sexually inactive after delivery will be similar to 
the probability of being sexually inactive at that specific age, and this holds true for the 
other transitions to the other alive health states too. Women in all health states other than 
the death states can transition to the death state because of background causes of 
mortality. The probabilities of death for each age group in Ethiopia were collected from 
the WHO life table (for 2016) for each age group, and this was used for all regions without 
any variation or adjustment because there are no regional lifetables available (Table 2) 
(24). Background mortality was calculated by subtracting pregnancy-related deaths from 
overall mortality in the WHO life table. The probability of pregnancy-related death was 
taken from the EDHS. The cycle length for this model was one year because it adequately 
represents the relevant transitions between all health states. Tables 1–5 summarize the 
input parameters of the model.  
 
4.3. Data sources  
Transition Probabilities 
State-transition probabilities were extracted from the EDHS and published studies (see 
Table 1). The probability of becoming sexually active was taken from the number of 
women who were sexually active within the one-year period of the study. This probability 
ranged from 20.8% in the 15–20 age group to 85% for the 30–35 age group. It also ranged 
from 44.4% in Addis to 71.3% in Afar. However, the age-specific probability of sexual 
activity has not been provided for the regions in the EDHS. Thus, I assumed that the 
proportion of each age group for the regions would be the same as for the national level 
and determined the common factors for each age-specific group using the national 
average and the age-specific probabilities. Then, I either increased or decreased the 
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common factor depending on the way the regional average varied in relation to the 
national average.  
After becoming sexually active. a reproductive-age woman may start to use modern 
contraceptive methods, a probability that is again dependent on specific age group (Tables 
2 and 4). Among those who do not start using modern contraceptive methods, those who 
unintentionally failed to do so were considered to have an unmet need and the remainder 
were regarded as having failed to do so because they wanted to get pregnant. The 
probability of unmet need was also taken from the EDHS. The same calculation method 
was applied to find the age-specific probabilities in regions as that applied for the 
probability of becoming sexually active. Those who start modern contraceptive use have 
a 29.5% probability of discontinuing, of which 57% do so intentionally. The probability 
of getting pregnant within a year, both for intentional and unintentional non-users of 
contraception, was 85% (23). This probability of getting pregnant was adjusted for 
menopause and reached as low as 49% in the final five years of reproductive age (Table 
2). The probability of method failure was 2.2%, and this was considered to be the 
probability of getting pregnant while using modern contraception. Pregnancies that 
happen while on modern contraception and while not using modern contraception 
unintentionally were treated as unintended pregnancies. The probability of inducing 
abortion due to unintended pregnancy was 13% (25), with the remaining pregnancies 
continuing. There is a 15% chance of pregnancies being delivered after complications 
while a few mothers died from pregnancy-related complications (26); the remaining 
mothers deliver safely. Intended pregnancies will have the same probability of 
complications as the unintended ones, but there will be no induced abortions.  
 
Table 1. Input parameters for Markov model 




Probabilities     
Probability of death from induced abortion 0.002 0.0015–0.0025 Beta (26) 
Probability of discontinuing use of modern 
contraceptives 0.295 0.2213–0.3688 Beta (13) 
Probability of discontinuing use of modern 
contraceptives unintentionally  0.432 0.426–0.71 Beta (13) 
Probability of inducing abortion for unintended 
pregnancy 0.13 0.0975–0.1625 Beta (25) 
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Probability of modern contraceptive failure and 
getting pregnant 0.022 0.0165–0.0275 Beta (13) 
Probability of a pregnancy complication 0.15 0.1125–0.1875 Beta (26) 
Discount rate  0.03 0.01–0.05 NA  
Cost     
Cost of abortion service $58  $29–87 Gamma  
Cost of managing complicated pregnancy $114 $57–170 Gamma (26) 
Cost of modern contraceptivesa $33 $17– 50 Gamma (27) 
Cost of safe pregnancy and delivery $58 $29–87 Gamma (27) 
Cost of demand generation for modern contraceptives  $3.512 $1.76–5.27  Gamma (28) 
     
Utilities     
The utility of survival and safe delivery 1 NA NA (29) 
The utility value for abortion  0.9 NA NA (29) 
The utility value for complicated pregnancy 0.824 NA NA (29) 
Utility value for death 0 NA NA (29) 
a  This cost varies by region with respect to the urban/rural composition of the population. 
 
Table 2. Age group–based transition probabilities of variables that did not vary 













15–19 0.1640 0.8500 0.0013 0.0003 
20–24 0.5762 0.8500 0.0014 0.0006 
25–29 0.7734 0.8500 0.0017 0.0007 
30–34 0.7668 0.7965 0.0022 0.0010 
35–39 0.6449 0.7574 0.0035 0.0011 
40–44 0.6139 0.6715 0.0043 0.0011 
45–49 0.3634 0.4930 0.0052 0.0008 
 
Health Outcomes 
The utility values and disability weights were all extracted from the Global Burden of 
Disease (GBD) study for 2015 (29). For the model, I chose to estimate outcomes in 
QALYs. To find the weight of quality of life, I used the disability weights that I found in 
the GBD table for each specific disease and subtracted it from 1. The quality of life value 
for death was 0, and for safe delivery a quality of life value of 1 was given. The quality 
of life weight for complicated pregnancy was found by a weighted average computation 
method. I extracted data about the prevalence of complicated pregnancy and the 
proportion of each type of pregnancy-related complication in total complicated 
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pregnancies in Ethiopia from the Ethiopian emergency obstetric and newborn care report 
of 2016 (26). I then looked for the respective disability weight for these pregnancy 
complications. The computed weighted average was then taken as the disability weight 
of complicated pregnancy, from which the QALY associated with complicated pregnancy 
was found.  
Costs 
All costs are based on secondary data sources. Costs were considered only for modern 
contraceptive and pregnancy-related outcomes. I assumed that the other health states were 
not associated with any costs. Cost data for modern contraceptives was extracted from a 
costing study of publicly funded primary care facilities, departments, and exempted 
services in Ethiopia by Berman et al. (27). The cost of modern contraceptives included 
direct medical costs for intentional modern contraception, which is composed of the costs 
of the drug and supply, human resources, and the cost of providing modern contraception 
for one year. Other costs were the costs needed for offices, electricity, running water, etc., 
to deliver the services (27).  
The cost value provided in Berman et al. is a national-level figure and I wanted to estimate 
how this cost would vary by region, especially depending on the urban/rural composition 
of the regions. I could not find relevant Ethiopian data on regional variation in costs. A 
study conducted in Kenya looked at contextual variation in the costs of a community 
health strategy while being implemented in rural, peri-urban, and nomadic areas. It 
showed that implementing a community health strategy program in rural and nomadic 
areas cost 7.2 and 6.4 times more, respectively, than in the peri-urban area (28). I used 
this ratio to vary the cost of modern contraceptives among regions by applying the same 
ratio of costs on the human resource portion of the costs by using the urban/rural or 
urban/nomadic composition of each region in Ethiopia. Information on the national and 
regional urban/rural composition was extracted from a population projection provided by 
the Ethiopian Central Statistics Agency (30). I treated the cost of modern contraception 
extracted from the Berman et al. study as national, and I used the national urban/rural 
composition to determine the urban cost of modern contraception, which I then used to 
calculate the costs in other regions.  
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I also wanted to include the cost of demand generation. Studies about the cost of demand 
generation per unit increment in the coverage of modern contraception was not available. 
The cost for demand generation in my study was therefore taken from the above study, in 
which the cost of implementing a community health strategy was identified and the per 
capita annual cost for its implementation was treated as the per capita cost needed for 
demand generation; the same urban/rural or urban/nomadic composition was also used 
for this one (28). The cost of pregnancy includes the cost needed for four antenatal care 
follow-ups and for delivery. The assumption in this study is that a mother who delivers 
will have attended all four antenatal care visits (27). All the services were assumed to be 
delivered at health-center level because the majority of the family planning, antenatal 
care, and delivery services take place at the health-center level, as per the EDHS 2016. 
The cost of complicated pregnancy was taken from the Emergency Maternal Obstetric 
and Neonatal Care assessment study conducted in 2016 (26). Because of the absence of 
recent and trusted cost data for abortions, I assumed its cost to be similar to the cost of 
delivery. All costs were adjusted for inflation and then converted to 2016 US dollars 
(US$) using official exchange rates and with the World Bank annual consumer price 
index (31).  
The budget impact of both the status quo coverage and the intervention coverage in all 
regions and at national level was computed by using the number of 15-year-old females 
in each population. I used the single-age population projection data for the year 2016 that 
the Ethiopian Ministry of Health collected from the Ethiopian Central Statistics Agency. 
The agency prepared this single-age population projection on the basis of the 2007 census 
and demographic health surveys that had been conducted prior to the projection. The five-
year-based population projections from 2007 to 2037 are available online from the official 
website of the agency (30). The total cost needed for both the status quo level and the 
intervention coverage will then be the product of the size of the 15-year-old female 
population and the total costs needed for a single 15-year-old female over her 
reproductive years. The difference between the costs for the intervention and the status 
quo level will give the incremental cost.  
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4.4. Sensitivity analysis 
I did both deterministic and probabilistic sensitivity analyses to identify which of the 
parameters could substantially influence the outcomes and to assess the uncertainty of the 
model’s parameters. In the deterministic analysis, I conducted a one-way sensitivity 
analysis, the results of which are presented as a tornado diagram, with several relevant 
parameters in the model varied in ranges of plausible values. As most of the parameters 
used did not have available 95% confidence intervals, I used plus/minus 25% for 
transition probabilities and plus/minus 50% for costs to provide a range for the sensitivity 
analysis (Table 1)(32). When the willingness-to-pay (WTP) threshold line is crossed by 
the tornado in a tornado diagram, it shows that the intervention will not be cost-effective 
for the value of that specific variable beyond the threshold. Thus, a variable that crosses 
the WTP is specifically seen in detail to determine the value beyond which the 
intervention would be not cost-effective. In the probabilistic sensitivity analysis, beta 
distribution was used for the transition probabilities and gamma distribution was used for 
cost variables, using the above-mentioned approach to include the standard errors. All 
parameters were varied simultaneously within their respective probability distributions. 
A Monte Carlo simulation was used to create 10,000 iterations for which the expected 
outcomes were calculated.  
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Table 3. Age group–based probability of becoming sexually active for all regions and national level (p_SA) 
Age Tigray Afar Amhara Oromia Somali B. Gumuz SNNP Gambela Harari AA DD National 
15–19 0.20 0.23 0.22 0.22 0.22 0.22 0.20 0.20 0.20 0.14 0.18 0.21 
20–24 0.62 0.71 0.68 0.69 0.67 0.71 0.64 0.64 0.63 0.44 0.58 0.65 
25–29 0.79 0.90 0.87 0.87 0.85 0.90 0.81 0.81 0.81 0.56 0.74 0.83 
30–34 0.81 0.93 0.89 0.90 0.87 0.92 0.83 0.83 0.82 0.58 0.75 0.85 
35–39 0.78 0.90 0.86 0.87 0.84 0.89 0.81 0.81 0.80 0.56 0.73 0.83 
40–44 0.75 0.86 0.83 0.83 0.81 0.85 0.77 0.77 0.77 0.54 0.70 0.79 
45–49 0.68 0.79 0.75 0.76 0.74 0.78 0.70 0.70 0.70 0.49 0.64 0.72 
B. Gumuz Benishangul Gumuz, SNNP – South Nations, nationalities and population, AA – Addis Ababa, DD – Dire Dawa  
Table 4. Age group–based probability of starting use of modern contraceptives (p_MC) 
Age Tigray Afar Amhara Oromia Somali B. Gumuz SNNP Gambela Harari AA DD National 
15–19 0.04 0.02 0.06 0.04 0.00 0.04 0.05 0.05 0.04 0.04 0.03 0.04 
20–24 0.15 0.06 0.21 0.13 0.01 0.14 0.17 0.17 0.13 0.15 0.12 0.16 
25–29 0.21 0.08 0.28 0.18 0.01 0.18 0.22 0.22 0.17 0.20 0.16 0.21 
30–34 0.20 0.08 0.28 0.17 0.01 0.18 0.22 0.22 0.17 0.19 0.16 0.21 
35–39 0.17 0.07 0.24 0.15 0.01 0.15 0.19 0.19 0.14 0.16 0.13 0.17 
40–44 0.16 0.07 0.23 0.14 0.01 0.15 0.18 0.18 0.13 0.16 0.13 0.17 
45–49 0.10 0.04 0.13 0.08 0.00 0.09 0.10 0.11 0.08 0.09 0.07 0.10 
B. Gumuz Benishangul Gumuz, SNNP – South Nations, nationalities and population, AA – Addis Ababa, DD – Dire Dawa  
Table 5. Age group–based probability of not starting use of modern contraceptive due to unmet need (p_UNC) 
Age Tigray Afar Amhara Oromia Somali B. Gumuz SNNP Gambela Harari AA DD National 
15–19 0.02 0.02 0.02 0.04 0.02 0.03 0.03 0.03 0.03 0.01 0.02 0.03 
20–24 0.06 0.06 0.06 0.10 0.04 0.08 0.07 0.08 0.07 0.04 0.06 0.07 
25–29 0.08 0.09 0.09 0.15 0.06 0.11 0.10 0.12 0.10 0.05 0.09 0.11 
30–34 0.10 0.11 0.11 0.19 0.08 0.14 0.12 0.14 0.12 0.07 0.11 0.13 
35–39 0.11 0.12 0.11 0.19 0.08 0.14 0.13 0.15 0.13 0.07 0.11 0.14 
40–44 0.09 0.10 0.10 0.17 0.07 0.12 0.11 0.13 0.11 0.06 0.10 0.12 
45–49 0.06 0.07 0.07 0.12 0.05 0.09 0.08 0.09 0.08 0.04 0.07 0.08 




5.1. Base-case analysis 
The intervention of scaling up modern contraceptive coverage to 55% dominates the 
status quo coverage because it has lower costs and higher QALYs at the national level 
(Figure 3). This also holds true for all regions; the intervention is cost saving in all regions, 
as shown in Table 6. Nationally, for a single 15-year-old female, it would cost $672 in 
total to meet the intervention coverage during her reproductive years, while the total cost 
of status quo coverage is $718. The total cost of providing modern contraceptives for the 
reproductive life of a 15-year-old female with the scaled-up coverage is highest in Oromia 
($687) and lowest in Addis Ababa, the capital ($513). The total costs for both the 
intervention and the status quo coverage vary by region. This difference in cost drops 
when the intervention is implemented, however. The range and the standard deviation 
among the regions in the status quo level of coverage are $246 and $64, respectively, 
while in the intervention they are $174 and $49. The same holds true with regard to 
effectiveness; the range and standard deviation among the regions in the status quo level 
is 0.22 and 0.1 QALY while it is close to zero on the intervention side because the total 
QALY gained over the whole cycle is almost the same in all the regions. 
 














55% Coverage Status quo Not Dominated
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Table 6. Base-case analysis of incremental cost, incremental effectiveness, and 
ICER for all regions 
Region Cost Effectiveness ICER 
Status 
quo 
Intervention Incremental Status 
quo 
Intervention Incremental 
B. Gumuz 752.2 680.6 -71.6 20.63 20.80 0.17 -425.0 
Afar 780.3 685.7 -94.6 20.57 20.80 0.23 -418.7 
Harari 697.6 633.4 -64.2 20.66 20.81 0.15 -411.9 
Gambela 696.9 646.9 -50.0 20.68 20.81 0.13 -370.9 
Amhara 730.9 686.2 -44.7 20.68 20.80 0.12 -368.8 
DD 656.5 606.1 -50.4 20.68 20.82 0.14 -350.6 
Oromia 745.0 687.3 -57.7 20.64 20.80 0.16 -342.9 
Somali 760.6 674.8 -85.8 20.55 20.81 0.26 -337.9 
SNNP 710.0 670.7 -39.3 20.68 20.81 0.13 -290.4 
Tigray 694.4 654.7 -39.7 20.68 20.82 0.14 -290.1 
AA 533.9 513.4 -20.5 20.77 20.86 0.09 -222.9 
National 718.4 672.0 -46.4 20.67 20.81 0.14 -321.8 
 
The QALYs gained from the intervention’s impact due to the reduction in unwanted 
pregnancies and related outcomes range from 0.1 QALY in Addis Ababa to 0.26 QALY 
in Somali region (Table 6). When the intervention is implemented, approximately 0.75 
million unintended pregnancies will be averted nationally over the reproductive life of 
the 15-year-old females who started the cohort (Table 7). This total comprises regional 
figures ranging from 1,622 in Harari region to approximately 500,000 in Oromia. There 
will also be 97,000 averted induced abortions nationally, ranging from 211 in Harari to 
63,000 in Oromia. The number of averted complicated pregnancies ranges from 2,500 in 
Harari to 440,000 in Oromia. Close to a million complicated pregnancies will also be 
averted nationally. In Somali region, there will be 83,000 fewer complicated pregnancies 
because of the intervention. In addition, a total of 5,880 maternal deaths will be averted. 
These reductions in unwanted pregnancy–related outcomes will occur in all regions, as 
shown in Table 7. The regions with higher population numbers will see the greatest 
reduction in unintended pregnancies and induced abortions. However, averted unintended 
pregnancies and averted induced abortions in Somali region are unusual in that they will 
see a lower reduction than some of the regions with higher populations. Percentage wise, 
there will be at least a 30% reduction in unwanted pregnancies and induced abortions in 
all regions except Somali and Addis Ababa region, where this figure is approximately 
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10% (Figure 4). There will also be at least a 40% reduction in complicated pregnancies 
and maternal deaths in all regions (Figure 5).  
Table 7. Number of averted clinical outcomes by intervention in each region and at 
national level 












Harari 1,622 211 2,525 15 
Gambela 3,283 427 3,826 23 
Dire Dawa 2,290 298 4,519 27 
Ben. Gumuz 9,823 1,277 12,817 77 
Afar 11,244 1,462 23,733 142 
Addis Ababa 3,255 423 16,279 97 
Somali 5,736 746 82,578 491 
Tigray 29,073 3,779 53,653 321 
Amhara 125,005 16,251 177,818 1,064 
SNNP 146,696 19,070 203,154 1,222 
Oromia 489,505 63,636 439,059 2,683 
National 746,970 97,106 975,886 5,880 
SNNP – southern nation nationalities and peoples’  
 
Figure 4. Percentage reduction in unintended pregnancies and induced abortions 
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Figure 5. Percentage reduction in complicated pregnancies and maternal deaths 
when the intervention is implemented 
Budget impact 
The estimated budget needed to implement the intervention for 15-year-old reproductive-
age females over their reproductive life at the national level is US$710 million. This is 
the budget needed to implement the strategy for the starting cohort of 1.06 million 15-
year-old females over their reproductive life (that is, until they reach 49). This cost ranges 
from as low as US$1.6 million in Harari to US$290 million in Oromia, the regions with 
the smallest and largest numbers of 15-year-old females, respectively. The costs needed 
for the implementation of the intervention in each region are presented in Table 8.  
Table 8. Budget impact. Total 35-year cost, average per-one-year cost of 
implementing the intervention, and total and per capita costs saved for cohort of 15-
year-old females in all regions in Ethiopia 
Regions Total costs* Costs/year* Costs saved*  
Per capita 
costs saved  
Harari 1,578,000 45,000 160,000 64 
Dire Dawa 2,824,000 81,000 235,000 50 
Gambela 2,864,000 82,000 221,000 50 
Benishangul 8,252,000 236,000 868,000 71 
Afar 11,301,000 323,000 1,559,000 95 
Addis Ababa 11,946,000 341,000 477,000 21 
Somali 33,060,000 945,000 4,204,000 86 
Tigray 38,961,000 1,113,000 2,363,000 40 
SNNP 155,773,000 4,451,000 9,128,000 39 
Amhara 158,355,000 4,524,000 10,315,000 45 
Oromia 290,026,000 8,286,000 24,348,000 58 
National  710,277,000 20,294,000 49,043,000 46 






Complicated pregnancy Maternal death
Amhara Addis Ababa Gambela SNNP Tigray Dire Dawa
Harari Ben. Gumuz Oromia Afar Somali National
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According to the baseline analysis, the intervention is cost saving in all regions and at the 
national level, as shown in Table 8. Using the population projection data I have for the 
number of 15-year-old females in each region for the year 2016, scaling up modern 
contraceptive prevalence to 55% throughout their reproductive life will result in savings 
of about US$49 million at the national level. The amount of money saved ranges from as 
little as US$160,000 in Harari to as much as US$24.3 million in Oromia. However, as 
shown in the same table, the per capita cost saved ranges from as little as US$20 in Addis 
Ababa to as much as US$95 in Afar. 
5.2. Sensitivity analysis 
The univariate sensitivity analysis shown in Figure 6 reveals that the ICER value is most 
sensitive to the variables cost of modern contraceptives and cost of delivery. Given a 
WTP level of US$380, none of the variation in the given variables will make the 
intervention a cost-ineffective alternative in the national model. However, for some 
regions, the cost of modern contraception and cost of safe pregnancy and delivery will 
cross the WTP threshold (Figures 7–8). The intervention will not be cost effective in 
Addis Ababa and SNNP if the cost of modern contraception is above US$39 and US$50, 
respectively, because the ICER value will be above the WTP if the costs go beyond those 
amounts (Figures 7 and 8). The one-way sensitivity analysis performed on the national 
model with regard to the impact of variation of cost of modern contraception on the cost-
effectiveness of the intervention shows that it is cost-effective throughout the range of the 




Figure 6. Tornado diagram of the national model 
 
 
Figure 7. One-way sensitivity analysis of the cost of modern contraceptives vs. 







Figure 8. One-way sensitivity analysis of the cost of modern contraceptives vs. 
ICER for SNNP 
 
 
Figure 9. One-way sensitivity analysis of cost of modern contraceptives vs. ICER 
for the national model 
The results from the probabilistic sensitivity analysis (Monte Carlo simulations with 
10,000 iterations) show that there is a 65% probability that the intervention will be a cost-
saving option, while it is cost-effective 78% of the time (Figure 10). However, there is a 
22% probability that the intervention will not be cost-effective since the ICER value will 
pass the WTP threshold of $380 per QALY even though it results in a better QALY gain. 
The intervention has a 65% probability of being cost-effective even when the WTP is 
zero, and this probability that the intervention will be cost-effective increases as the WTP 
is increased, as shown in Figure 11, and could reach as high as 90% if the WTP is 
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increased to US$800 per QALY. This result is the same if not better in all regions. The 
sensitivity analysis results for the regions are presented in Annex 3. 
 
Figure 10. Incremental cost-effectiveness, intervention vs. status quo level, from 
probabilistic sensitivity analysis of the national model 
 
 





6. Discussion  
On the basis of the results from the baseline analysis of the model, scaling up the coverage 
of modern contraception in Ethiopia is cost saving in all regions, dominating the status 
quo coverage level. This result was robust in the probabilistic sensitivity analysis for the 
national model and as well for all regions. The QALY gained in the regions was highest 
in Somali. This could be explained by the fact that the status quo modern contraceptive 
coverage level is lowest in Somali, meaning that the region benefits comparatively better 
when the modern contraceptive coverage is increased to a 55% across all regions. A 
higher QALY gain also appears in other regions with lower status quo modern 
contraceptive coverage levels.  
The analysis shows that larger regions with a larger proportion of rural inhabitants have 
higher costs than do regions with a large proportion of urban inhabitants. This is because 
the cost of modern contraceptives is higher in regions with a proportionately larger rural 
population. 
Although we cannot immediately state where in the regions the intervention is most cost-
effective using the ICER values that are negative, we can comment on where the 
intervention can be implemented for better cost saving and where a better incremental 
QALY can be generated. The intervention has narrowed the difference among the total 
per capita costs needed for the intervention among the regions, as shown by the decrease 
in the range and standard deviation of costs. This may likely be because of equalization 
of the modern contraceptive coverage level, which varies in the status quo. The remaining 
variations in regional total per capita costs for the intervention after equalization of 
coverage are most probably due to regional differences in the cost of services. Somali and 
Afar are regions where the status quo coverage is low, and this, combined with the large 
proportion of rural inhabitants, seems to have contributed to the comparatively higher per 
capita costs saved.  
When it comes to total health benefits, Somali and Afar are the two regions where more 
QALYs are generated, which may also be attributed to their lower status quo coverage. 
However, looking into the clinical outcomes, Somali region has the lowest percentage 
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reduction in unintended pregnancies and induced abortions. This is because, although 
Somali region has very low modern contraceptive coverage, the unmet need in this region 
is also lower than the other regions. One may say that the problem in this region is lack 
of demand rather than simply low modern contraceptive coverage. Thus, the reduction in 
unintended pregnancies in this region will not be significant when the intervention is 
implemented because the number of unintended pregnancies is comparatively low from 
the start in the status quo coverage. However, when we increase the coverage to 55%, the 
number of wanted pregnancies will also be reduced, from which the greater proportion of 
the reduction in complicated pregnancies and maternal deaths is derived in this region, 
allowing it to be  the region where the total health gain is highest. 
Scaling up modern contraceptives has been found to be cost-effective by other economic 
modeling studies. Creating universal access to contraceptives in Uganda was found to be 
cost-effective and cost saving compared to the then existing contraceptive program. It 
resulted in a 0.37 incremental disability-adjusted life expectancy with a cost of $49 lesser  
than the program in place (33). Similar findings were also seen in another study conducted 
in Uganda and Indonesia. In that study, rather than universal access, the interventions 
increased modern contraceptive coverage from the status quo level by 25%, 50%, 75%, 
and 100%. The study had robust finding that the interventions were cost saving almost 
100% of the time during the probabilistic sensitivity analysis (34). Even though the results 
of my probabilistic sensitivity analysis do not result in cost-effectiveness 100% of the 
time, they are still robust in that most of the time the intervention is cost saving. The 
results are thus comparable with those of the above-mentioned studies. 
If the assumptions and model estimates used in this study are valid, health sector officials 
in Ethiopia, both at the national and regional level, may find these results relevant and 
might use them as supporting evidence to convince the government that investing more 
in modern contraceptives would result in better health benefits, reduced geographic 
inequality, and saved money. Looking into the results of the national model, an 
investment of US$20 million per year yields a cost saving of approximately US$1.4 
million and improved health outcomes, such as an estimated 21,000 fewer unintended 
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pregnancies, 2,770 averted abortions, close to 28,000 averted pregnancy complications, 
and 170 fewer maternal deaths. 
Since this intervention is cost saving, it suggests that scaling up modern contraceptives to 
55% prevalence is good value for money. However, the decision by policymakers to shift 
money from other health interventions to scaling up modern contraceptives requires 
consideration of other factors, such as the intervention’s impact on financial risk 
protection and equitable distribution across socioeconomic statuses (35, 36).  
One published economic evaluation study conducted at the national level in Ethiopia to 
check the cost-effectiveness of scaling up coverage of maternal and neonatal health 
services by 20% from the baseline showed that most of the health interventions included 
in the study, with the exception of calcium supplementation for preeclampsia and 
eclampsia, were cost-effective (based on specified GDP criteria for cost-effectiveness), 
some highly so. However, none of the interventions included in the study were identified 
as cost saving (37). As suggested for the economically evaluated interventions in the study 
by Memirie et al., modern contraception is an acceptable health intervention in the context 
of Ethiopia and is already part of the essential health service package there. However, the 
findings of this study also suggest that scaling up is worthy of consideration.  
 
Figure 12. Incremental effect and incremental cost in all regions resulting from the 
intervention 
One of the strengths of this study is the fact that it is the first subnational cost-
effectiveness analysis of the scaling up of modern contraceptive coverage, at least in low- 





























modern contraceptives has been examined by few economic evaluation studies. However, 
given the wide range in modern contraceptive coverage between regions within a country, 
the interventions have the possibility of different outcomes in different regions. Thus, the 
fact that this study is subnational makes it more informative with regard to the details of 
the cost- effectiveness of the intervention. As shown in Figure 12, Afar and Somali are 
far to the right on the cost-effectiveness plane, showing that the intervention is most cost- 
effective there, and that Addis Ababa is close to the origin, showing that the intervention 
is least cost-effective there. 
Cost data are mostly from local, Ethiopian studies, with the exception of the cost data for 
demand generation, which came from a neighboring country. The proximity of the data 
source may make the study more useful for local decision makers than studies using cost 
data from other, more distant sources. Economic evaluation studies carried out with cost 
data from other countries are relatively difficult to use as evidence for local decision 
making (38). Thus, this study has greater value in this regard.  
In this study, I have followed CHEERS format, which is the recommended reporting 
guideline for economic evaluation. Consequently, the study can be easily understood and 
evaluated by the economic evaluation study community, which will make it easier to 
compare the results with other economic evaluation studies. This is another strength of 
this study. 
The study also has some limitations, however. One of these is that the benefits of 
contraceptives considered in this study were solely health benefits concerning the 
aversion of unintended pregnancies and related outcomes. Cost effectiveness analysis 
applied to health outcome only will underestimate the overall value of the intervention 
(39). Contraceptives have other health benefits to women, however, such as reducing the 
risk of endometrial and ovarian cancers, contributing to the treatment of menstrual-related 
symptoms, and preventing sexually transmitted diseases. Using contraceptives also helps 
to reduce child deaths by enabling mothers to improve the care given to children (40). 
Progress in gender equality gained because of better education and economic 
empowerment are also among important non-health benefits of contraceptive utilization 
(9) that were not incorporated into this study. On the other hand, there are also potential 
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health-related risks with prolonged use of different types of modern contraceptive 
methods. Increased risk of breast cancer and impact on bone mineral density are 
encountered while using pills, and there is risk of pelvic inflammatory disease with the 
use of IUDs. These disadvantages of contraceptives were also not incorporated into this 
study (40). However, such disadvantages do not, I believe, outweigh the above-mentioned 
benefits; indeed, overall, my model may have underestimated the potential cost-
effectiveness of scaling up modern contraceptive coverage.  
A further limitation is that the study considered an increase in modern contraceptive 
coverage from a low initial rate, such as 1%, to a relatively high level of coverage (55%), 
and this may be unrealistic from a short-term perspective. I also assumed an instantaneous 
scale-up in modern contraceptive coverage and that such coverage remained constant 
throughout the whole cycle, which is not realistic. This was done to create a similar target 
coverage for the regions. Had I applied a constant rate of increment in coverage per year, 
the inter-regional differences in coverage would have remained the same at the end of the 
cycle, making equalization of coverage among regions impossible and comparison 
unfeasible. Changing the model structure and scaling-up pathways could have a 
substantial impact on the total costs, thus affecting the results of the cost-effectiveness 
analysis.  
My study also did not consider the increasing marginal cost of scaling up modern 
contraceptives. The cost needed to increase coverage from 10 to 20 and from 40 to 50 
was assumed to be the same in this study because of the absence of trusted local marginal 
cost data. However, marginal costs will not be constant. The study may thus overestimate 
the cost-effectiveness of the intervention. It would be much better to consider the 
incorporation of data collection on marginal costs in future models to determine the 
subnational cost-effectiveness of scaling-up interventions.  
The fact that the model did not consider method mix of  modern contraceptive methods, 
changing over the years as per the Ministry of Health’s plan, is another limitation of this 
study. The lack of trusted local cost data and the complexity of incorporating the cost 
variation along with the change in method mix were the reasons for the exclusion of this 
consideration. In this study, the cost of contraception is one of the parameters to which 
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the ICER value is sensitive; thus, the cost I used may have led to under- or overestimating 
the cost-effectiveness of the intervention. This should be considered in future modeling 
practice. 
This study might have had a better evidence base had the cost data not been secondary. 
Primary cost data collection in all regions was beyond the scope and timeframe of this 
thesis. In addition, the absence of some regional data, such as age-specific transition 
probabilities and regional cost variations, persuaded me to compute them with some 
assumptions. Even though I tried to make my assumptions as close to reality as possible, 
the lack of data suggests that my results should be interpreted with caution.  
The Wafula et al. study from which I extracted the cost data of demand generation is from 
Kenya. It was conducted to assess the contextual variation in costs for a community health 
strategy and not specifically for modern contraceptive demand generation. Thus, the cost 
of demand generation could be higher or lower and may affect the budget estimates I have 
produced. Kenya’s urban/rural and the urban/nomadic area cost relation may also be 
different from Ethiopia’s. Thus, the impact of variation in this cost data could be large 
and especially significant in regions like Somali where the increment in contraceptive 
coverage depends on demand generation. Thus, my choice of data from the Kenyan study 
may have had a definite impact on the regional analysis of the intervention’s cost-
effectiveness. 
Finally, my results indicate that the federal government and partner organizations should 
focus on scaling up modern contraceptive coverage in all regions to address unmet need. 
In regions like Somali, however, increasing coverage would not be enough, and 






7. Conclusion  
Scaling up and equalizing modern contraceptive coverage in all regions of Ethiopia is 
cost-effective and could also be cost saving both at the regional and national levels. In 
addition to the enormous health benefits that will be gained, regional governments will 
save money by investing in increased coverage of modern contraception. Although the 
intervention has good value for money, it is also necessary to look at other factors, such 
as the impact on financial risk protection, before shifting money from other areas of 
investment to this intervention. The results of this study can serve as evidence for budget 
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Annex 1: CHEERS Checklist 
 ISPOR CHEERS Task Force Report, Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS)—Explanation and Elaboration  
Section/item Item 




Title and abstract    
Title 1 Identify the study as an economic evaluation or use more  
  specific terms, such as “cost-effectiveness analysis,” and  
  describe the interventions compared. Cover page 
Abstract 2 Provide a structured summary of objectives, perspective,  
  setting, methods (including study design and inputs), results  
  (including base case and uncertainty analyses), and  
  conclusions. iii-v 
Introduction    
Background and 3 Provide an explicit statement of the broader context for the  
objectives  study.  
  
Present the study question and its relevance for health policy 




Methods    
Target population  
and 4 Describe characteristics of the base-case population and  
subgroups  subgroups analyzed, including why they were chosen. 6/11 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s)  
  need(s) to be made. NA 
Study perspective 6 Describe the perspective of the study and relate this to the  
  costs being evaluated. 6/11 
Comparators 7 Describe the interventions or strategies being compared and  
  state why they were chosen. 6/10 
Time horizon 8 State the time horizon(s) over which costs and consequences  
  are being evaluated and say why appropriate. 6/5 
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Discount rate 9 Report the choice of discount rate(s) used for costs and  
  outcomes and say why appropriate. 6/22 
Choice of health 10 Describe what outcomes were used as the measure(s) of  
outcomes  benefit in the evaluation and their relevance for the type of  
  analysis performed. 6/15 
Measurement of 11a Single study-based estimates: Describe fully the design  
effectiveness  features of the single effectiveness study and why the single  
  study was a sufficient source of clinical effectiveness data. 11/2 
 11b Synthesis-based estimates: Describe fully the methods used for  
  identification of included studies and synthesis of clinical 
  effectiveness data.                                                                            NA 
Measurement and 12 
If applicable, describe the population and methods used to  
 
valuation of  
preference  elicit preferences for outcomes. 
based outcomes                                                                                                        NA 
Estimating resources 13a Single study-based economic evaluation: Describe approaches  
and costs  used to estimate resource use associated with the alternative 
  interventions. Describe primary or secondary research methods 
  for valuing each resource item in terms of its unit cost. 
  Describe any adjustments made to approximate to opportunity 
  costs.                                                                                                 12/4 
 13b Model-based economic evaluation: Describe approaches and  
  data sources used to estimate resource use associated with 
  model health states. Describe primary or secondary research 
  methods for valuing each resource item in terms of its unit 
  cost. Describe any adjustments made to approximate to 
  opportunity costs.                                                                            NA 
Currency, price date, 14 Report the dates of the estimated resource quantities and unit  
and conversion  costs. Describe methods for adjusting estimated unit costs to 
  the year of reported costs if necessary. Describe methods for 
  converting costs into a common currency base and the 
  exchange rate. 13/15 
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Choice of model 15 Describe and give reasons for the specific type of decision- 
  analytical model used. Providing a figure to show model 
  structure is strongly recommended                                               8 
Assumptions 16 Describe all structural or other assumptions underpinning the  
  decision-analytical model.                                                             8-9                                                      
Analytical methods 17 Describe all analytical methods supporting the evaluation. This   
  could include methods for dealing with skewed, missing, or 
  censored data; extrapolation methods; methods for pooling 
  data; approaches to validate or make adjustments (such as half- 
  cycle corrections) to a model; and methods for handling 
  population heterogeneity and uncertainty.                                    10-13 
Results    
Study parameters 18 Report the values, ranges, references, and, if used, probability 
  distributions for all parameters. Report reasons or sources for 
  distributions used to represent uncertainty where appropriate. 
  Providing a table to show the input values is strongly 
  recommended.                                                                                 11 
Incremental costs 
and 19 For each intervention, report mean values for the main  
outcomes  categories of estimated costs and outcomes of interest, as well 
  as mean differences between the comparator groups. If 
  applicable, report incremental cost-effectiveness ratios.               16-17 
Characterizing 20a Single study-based economic evaluation: Describe the effects  
uncertainty  of sampling uncertainty for the estimated incremental cost and 
  incremental effectiveness parameters, together with the impact      NA 
  of methodological assumptions (such as discount rate, study 
  perspective).                                                                                  20 
 20b Model-based economic evaluation: Describe the effects on the  
  results of uncertainty for all input parameters, and uncertainty 
Characterizing 21 
related to the structure of the model and assumptions. 20 
If applicable, report differences in costs, outcomes, or cost- 
heterogeneity  effectiveness that can be explained by variations between 
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  subgroups of patients with different baseline characteristics or 
  other observed variability in effects that are not reducible by 
  more information                                                                          20 
Discussion    
Study findings, 22 Summarize key study findings and describe how they support 
limitations,  the conclusions reached. Discuss limitations and the 
generalizability, and  generalizability of the findings and how the findings fit with 
current knowledge  current knowledge.                                                                        24 
Other    
Source of funding 23 Describe how the study was funded and the role of the funder 
  in the identification, design, conduct, and reporting of the 
Conflicts of interest 24 
analysis. Describe other non-monetary sources of support. NA 
Describe any potential for conflict of interest of study 
  contributors in accordance with journal policy. In the absence 
  of a journal policy, we recommend authors comply with 
  International Committee of Medical Journal Editors 












Annex 2: Markov model 
Figure 12. Markov model used in this study
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Annex 3: Probabilistic sensitivity analysis of regional models 























































Table 9. Current modern contraceptive coverage and 15-year-old female population projected by CSA, used for the 
analysis of clinical outcomes and budget impact 
 
Region 
Status quo modern 
contraceptive coverage 
2016 15-year-old female 
population 
Harari 20.2 2,492 
Dire Dawa 18.8 4,660 
Gambela 26.5 4,427 
Somali 1.0 48,993 
Addis Ababa 23.2 23,269 
Ben. Gumuz 21.9 12,124 
Afar 10.0 16,481 
Tigray 24.5 59,510 
Amhara 33.7 230,771 
SNNP 26.5 232,254 
Oromia 20.9 421,979 
National 24.8 1,056,960 
 
 
 
